A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax

被引：1

作者：

Sharpe, Chia ^{[1
]}

Elgamal, Sara ^{[1
]}

Fobare, Sydney ^{[2
]}

Furby, Casie ^{[1
]}

Long, Marissa ^{[1
]}

Bryant, Kinsey ^{[1
]}

Cheney, Carolyn ^{[1
]}

Lerma, James R. ^{[1
]}

Johnstone, Megan E. ^{[1
]}

Orry, Andrew ^{[3
]}

Lam, Polo Chun-Hung ^{[3
]}

Abagyan, Ruben ^{[3
]}

Kysil, Volodymyr ^{[4
]}

Gukasyan, Hovhannes ^{[4
]}

Mitkin, Oleg ^{[4
]}

Karapetian, Ruben ^{[4
]}

Ryakhovskiy, Alexey ^{[4
]}

Bulanova, Elena ^{[4
]}

Parchinsky, Vladislav ^{[4
]}

Ivachtchenko, Alexandre ^{[4
]}

Dokukina, Kate ^{[5
]}

Pushechnikov, Alexei ^{[4
]}

Savchuk, Nikolay ^{[5
]}

Dukes, Iain ^{[5
]}

Burd, Amy ^{[5
]}

Hertlein, Erin K. ^{[1
]}

Byrd, John C. ^{[1
]}

机构：

[1] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA

[2] Ohio State Univ, Med Scientist Training Program, Columbus, OH USA

[3] MolSoft LLC, San Diego, CA USA

[4] ChemDiv Inc, San Diego, CA USA

[5] Eilean Therapeut, Philadelphia, PA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189266

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] ROCK inhibitors synergize with the BCL2 inhibitor venetoclax for treatment of AML
Golla, Upendarrao
Patel, Satyam
Tukaramrao, Diwakar B.
Hengst, Jeremy
Restrepo, Juliana
Amin, Shantu
Desai, Dhimant
Dovat, Sinisa
Claxton, David
Sharma, Arati
CANCER RESEARCH, 2023, 83 (07)
[2] THE BCL2 INHIBITOR VENETOCLAX IS ACTIVE IN NON-HODGKIN LYMPHOMA
不详
CANCER DISCOVERY, 2017, 7 (03) : 244 - 244
[3] Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Anderson, Mary Ann
Tam, Constantine
Lew, Thomas E.
Juneja, Surender
Juneja, Manu
Westerman, David
Wall, Meaghan
Lade, Stephen
Gorelik, Alexandra
Huang, David C. S.
Seymour, John F.
Roberts, Andrew W.
BLOOD, 2017, 129 (25) : 3362 - 3370
[4] Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
XiaoYan Yue
Qingxiao Chen
JingSong He
Cancer Cell International, 20
[5] Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Yue, XiaoYan
Chen, Qingxiao
He, JingSong
CANCER CELL INTERNATIONAL, 2020, 20 (01)
[6] Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.
Lindeman, Geoffrey John
Lok, Sheau Wen
Bergin, Alice Ruth
Whittle, James Richard
Shackleton, Kylie
Sherman, Peter
Dawson, Sarah-Jane
Desai, Jayesh
Liew, Danny
Mann, Bruce
Murugasu, Anand
Roberts, Andrew Warwick
Rosenthal, Mark
Visvader, Jane
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[7] The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation
Liu, Peng
Zhao, Liwei
Zitvogel, Laurence
Kepp, Oliver
Kroemer, Guido
CELL DEATH AND DIFFERENTIATION, 2023, 30 (12): : 2447 - 2451
[8] The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation
Peng Liu
Liwei Zhao
Laurence Zitvogel
Oliver Kepp
Guido Kroemer
Cell Death & Differentiation, 2023, 30 (12) : 2447 - 2451
[9] Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor.
Brandhuber, Barbara
Ku, Karin
Lallena, Maria J.
Baquero, Carmen
Choy, Regina
Ebata, Kevin
Lin, Sophie Shu
Jiang, Lihua
Liu, Yanxin
Chen, Xiangling
Lou, Liguang
CANCER RESEARCH, 2021, 81 (13)
[10] Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Katharina T. Prochazka
Barbara Uhl
memo - Magazine of European Medical Oncology, 2022, 15 : 45 - 48

← 1 2 3 4 5 →